We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.

Settings

Save and close

JAX Frontend Platform

CD34+ Humanized NSG-FLT3 Mice

Females

Stock No: 703367 | NSG-FLT3

Contact: [email protected] | 1.800.422.6423 (US) | 1.207.288.5845 (International)

Overview

The NSG-FLT3 mouse model is a comprehensive myeloid cell model following CD34 humanization. This transgenic mouse model has had the endogenous mouse Flt3 receptor knocked out and a human FLT3 ligand expressing transgene knocked in, a critical ligand for immune cell development. Human CD34 hematopoietic stem cell engrafted NSG-FLT3 mice express a diverse set of myeloid cell lineages such as CD33+ myeloid progenitors, CD14+ monocytes, and both functional CD11c+ conventional and CD123+ plasmacytoid dendritic cells. Off-the-shelf female mice are available at 18 to 24 weeks of age.

Key Benefits

  • CD34+ engrafted NSG-FLT3 mice have high levels of T cells, Tregs, CD33+ myeloid cells, CD14+ monocytes, and CD56bright+/CD16- natural killer cells.
  • CD34+ engrafted NSG-FLT3L mice develop functionally active CD11c+ conventional and CD123+ plasmacytoid dendritic cells.
  • Readily engraftable with human cancer cell line derived and patient derived xenograft for preclinical therapeutic studies.

Research Applicatons

Immuno-oncology Autoimmune Disorders
Human Immune Function Infectious Disease
Diabetes Oncology
Stem Cell Biology

©2025 The Jackson Laboratory